Research.Patient.info
Hepatocellular Carcinoma Non-resectable research hub
2 indexed studies · 2 currently recruiting
- recruitingPHASE2
Atezolizumab/Bevacizumab Followed by On-demand TACE or Initial Synchronous Treatment With TACE and Atezolizumab/Bevacizumab
This study is looking at two ways to use a combination of medicines (atezolizumab and bevacizumab) and a procedure called TACE for people with liver cancer that can't be removed by surgery. It aims to see which approach works best.
Germany - recruitingPHASE2
Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC
This study is looking at a new way to treat a type of liver cancer that can't be removed with surgery. It combines two immunotherapy drugs, durvalumab and tremelimumab, with a radiation treatment called Y-90 SIRT. The aim is to see if this combination is safe and effective.
Germany